ReviewSynaptosome as a tool in Alzheimer’s disease research
Introduction
The major pathway of inter-neuronal communication is formed by what are known as chemical synapses, which are characterized by employment of a broad range of “neurotransmitters” and “neuropeptides” for propagation of signals in lieu of absence of any direct physical contact points between neurons. Structurally, a typical chemical synapse consists of an axon terminus or the presynapse, synaptic cleft and the postsynaptic density or the PSD (Harris and Littleton, 2015). The pre- and postsynaptic entities are uniquely distinguishable by visible densities along their corresponding cell membranes. Hence the presynapse is highly enriched in synaptic vesicles which store neurotransmitters, and mitochondria which are a bioenergetic source. Arrival of an action potential at the presynapse triggers release of neurotransmitters from the vesicles into the synaptic cleft in an intricate exocytosis-dependent and calcium-regulated process. The PSD has a dense collection of clustered receptors on its cytoplasmic surface that bind to the neurotransmitters present in the synaptic cleft and initiate the postsynaptic responses. Of note, communication through chemical synapses is plastic with dynamic short and long-term alterations in their signalling capacities, strengths and nature of downstream effector responses. It is not surprising then that chemical transmission in the nervous system is under a potent regulation mediated by complex and interlinked protein-driven molecular mechanisms, making them arguably one of the most complex molecular functional system known to biologists.
Alzheimer’s disease (AD) is among the primary causes of dementia in the aged population worldwide. Synapses are known to be a primary and early target in AD pathogenesis (DeKosky and Scheff, 1990, LaFerla and Oddo, 2005, Selkoe, 2002). In fact, prodromal loss of spines and structural alternations in synapse structure and functions are observed long before the onset of overt pathological hallmarks (such as amyloid plaques and neurofibrillary tangles) of the disease (Hsia et al., 1999, Terry et al., 1991). Importantly, loss of synapse structure and density (rather than plaque deposition, tangle accumulation or neuronal loss) is a strong correlate of cognitive, behavioural and memory deficits observed along the course of the disease (DeKosky and Scheff, 1990, Scheff et al., 1991, Terry et al., 1991). Not surprisingly then, AD is often attributed primarily as a degenerative disorder of the synapses (Selkoe, 2002). Several observations support this hypothesis; first, proteins and their fragments central to AD pathology; amyloid precursor protein (APP), amyloid beta peptides (Aβ) and pathogenic tau species are all localized in synaptic compartments (Fein et al., 2008, Henkins et al., 2012, Tai et al., 2014) and are secreted upon induction of synaptic activity (Cirrito et al., 2005, Cirrito et al., 2008, Sokolow et al., 2015). Second, connectivity, but not proximity, regulates propagation of the toxic species, indicating a trans-synaptic mechanism (Ahmed et al., 2014, Dujardin et al., 2014, Liu et al., 2012). Third, current therapeutic strategies against AD mainly focus upon preserving synaptic functions (Tan, 2014). It should be noted here that contemporary anti-AD drugs and therapies offer only symptomatic relief and currently no ameliorative therapy has proved to elucidate any disease-retarding or modifying properties. This is mainly due to the complex and varying influences of a plethora of wide-ranged genetic and environmental factors on the pathogenesis of AD (Crous-Bou et al., 2017, Ferreira et al., 2020). In this regard, a comprehensive understanding of the disease pathology, identification of specific biomarkers and therapeutic targets, and by extension, successful assembly of a suitable disease modifying strategy necessitates a complete picture of the fundamental role of synaptic deficits in the progression of AD and the molecular mechanisms and players involved.
Several novel instruments and techniques have been developed (and continue to be developed) specifically to study both the electrical and biochemical aspects of synaptic physiology, as well as their alterations in neuropathological states, particularly neurodegenerative conditions like AD. None of them have been more indispensable than the ex vivo neurobiochemical preparations of “synaptosomes”, subcellular brain fractions that are enriched in synaptic terminals. The present review attempts to summarize the knowledge leap achieved by synaptosomal research in AD. First, a brief outline of the biochemical technique for isolation of synaptosomes and their research utilities is provided; followed by a thorough analysis of the major findings of the studies that utilized synaptosomes as an ex vivo model in an effort to contribute to and further our understanding of the complex mechanisms of synaptic dysfunction that is central to AD pathology.
Section snippets
Biochemical isolation of synaptosomes and their application as a model for synaptic physiology
“Synaptosomes” are subcellular neurobiochemical preparations enriched in detached and resealed synaptic terminals that retain their metabolic and enzymatic activities. First isolated in late 1950s (Hebb and Whittaker, 1958), the initial protocol relied on a high-speed density gradient centrifugation for subcellular fractionation of the brain tissue (De Robertis et al., 1962, Gray and Whittaker, 1962, Whittaker et al., 1963, Whittaker et al., 1964). The procedure outlined in Fig. 1 still remains
Synaptosomal research in AD
The subsections below summarize the research studies that have utilized synaptosome as an ex vivo model focussing on various aspects of synaptic pathology in AD. In addition, Section 3.7 outlines synaptosomal studies that have evaluated the efficiencies of a plethora of anti-AD therapeutic measures.
Conclusion
It is clear that data from synaptosomal research have contributed immensely to our understanding of the fine attributes of synaptic pathology in AD, whether in prodromal stages of animal models or in case of surviving synapses of the cryopreserved brains of human subjects. One of the major conclusions from the use of synaptosomes as an ex vivo model of synaptic terminals is the extensive accumulation of both Aβ and tau species, particularly in glutamatergic synapses. In addition, synaptosomes
Acknowledgements
This work was supported by the Neurological Foundation of New Zealand (1835-PG) and the Department of Anatomy, University of Otago. The authors declare no conflict of interests.
References (261)
- et al.
Interaction between NH2-tau fragment and Aβ in Alzheimer’s disease mitochondria contributes to the synaptic deterioration
Neurobiol. Aging
(2012) - et al.
β-amyloid neurotoxicity is exacerbated during glycolysis inhibition and mitochondrial impairment in the rat hippocampus in vivo and in isolated nerve terminals: implications for alzheimer’s disease
Exp. Neurol.
(2002) - et al.
Loss of phospholipid asymmetry and elevated brain apoptotic protein levels in subjects with amnestic mild cognitive impairment and Alzheimer disease
Neurobiol. Dis.
(2008) Molecular membrane dynamics: Insights into synaptic function and neuropathological disease
Neurosci. Res.
(2018)- et al.
Monomeric amyloid-β reduced amyloid-β oligomer-induced synapse damage in neuronal cultures
Neurobiol. Dis.
(2018) - et al.
Calpain-1 and Calpain-2: The Yin and Yang of synaptic plasticity and neurodegeneration
Trends Neurosci.
(2016) - et al.
Methylene blue activates the PMCA activity and cross-interacts with amyloid β-peptide, blocking Aβ-mediated PMCA inhibition
Neuropharmacology
(2018) - et al.
Apolipoprotein E/Amyloid-β complex accumulates in alzheimer disease cortical synapses via apolipoprotein E receptors and is enhanced by APOE4
Am. J. Pathol.
(2019) - et al.
Synaptic amyloid-β oligomers precede p-Tau and differentiate high pathology control cases
Am. J. Pathol.
(2016) - et al.
Phosphoinositide kinase activities in synaptosomes prepared from brains of patients with Alzheimer’s disease and controls
Neurosci. Lett.
(1994)
β-amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-specific fashion: Implications to alzheimer′s disease
Biochem. Biophys. Res. Commun.
Aβ(25–35) peptide displays H2O2-like reactivity towards aqueous FE2+, nitroxide spin probes, and synaptosomal membrane proteins
Life Sci.
Modulation of phospholipid asymmetry in synaptosomal membranes by the lipid peroxidation products, 4-hydroxynonenal and acrolein: implications for Alzheimer’s disease
Brain Res.
The dynamic synapse
Neuron
Endocytosis is required for synaptic activity-dependent release of amyloid-β in vivo
Neuron
Synaptic activity regulates interstitial fluid amyloid-β levels in vivo
Neuron
Secreted amyloid precursor protein-α upregulates synaptic protein synthesis by a protein kinase G-dependent mechanism
Neurosci. Lett.
Analytical differential centrifugation: an analysis of the sedimentation properties of synaptosomes, mitochondria and lysosomes from rat brain homogenates
Arch. Biochem. Biophys.
Cyclin-dependent kinase 5 activator p25 Is generated during memory formation and is reduced at an early stage in Alzheimer’s disease
Biol. Psychiatry
Co-localization of amyloid beta and tau pathology in Alzheimer’s disease synaptosomes
Am. J. Pathol.
Disruption of glutamate receptors at Shank-postsynaptic platform in Alzheimer’s disease
Brain Res.
Mitochondrial base excision repair in mouse synaptosomes during normal aging and in a model of Alzheimer’s disease
Neurobiol. Aging
In vivo 2-deoxyglucose administration preserves glucose and glutamate transport and mitochondrial function in cortical synaptic terminals after exposure to amyloid β-peptide and iron: evidence for a stress response
Exp. Neurol.
Non-Aβ component of Alzheimer’s disease amyloid and amyloid beta peptides evoked poly(ADP-ribose) polymerase-dependent release of apoptosis-inducing factor from rat brain mitochondria
J. Physiol. Pharmacol.
Synaptosomal bioenergetic defects are associated with cognitive impairment in a transgenic rat model of early Alzheimer’s disease
J. Cereb. Blood Flow Metab.
Neuroinflammation, oxidative stress and the pathogenesis of Alzheimers Disease
Curr. Pharm. Des.
Isoform-specific hyperactivation of calpain-2 occurs presymptomatically at the synapse in Alzheimer’s disease mice and correlates with memory deficits in human subjects
Sci. Rep.
Dysfunction of cortical synapse-specific mitochondria in developing rats exposed to lead and its amelioration by ascorbate supplementation
Neuropsychiatr. Dis. Treat.
Reactive oxygen species-mediated loss of synaptic Akt1 signaling leads to deficient activity-dependent protein translation early in Alzheimer’s disease
Antioxidants Redox Signal.
A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity
Acta Neuropathol.
UV irradiation accelerates amyloid precursor protein (APP) processing and disrupts APP axonal transport
J. Neurosci.
A NH2 tau fragment targets neuronal mitochondria at AD synapses: possible implications for neurodegeneration
J. Alzheimer’s Dis.
Mitochondria in excitatory and inhibitory synapses have similar susceptibility to amyloid-β peptides modeling Alzheimer’s disease
J. Alzheimer’s Dis.
Discussion of the role of the extracellular signal-regulated kinase-phospholipase A2 pathway in production of reactive oxygen species in Alzheimer’s disease
Neurochem. Res.
Uptake and release of norepinephrine by rat brain tisue fractions prepared by ultrafiltration
J. Neurochem.
Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-Aβ antibody
J. Clin. Invest.
Tyr(682) in the intracellular domain of APP regulates amyloidogenic APP processing in vivo
PLoS One
CAMP-inhibits cytoplasmic phospholipase A2 and protects neurons against amyloid-β-induced synapse damage
Biology (Basel)
Calpain-1 and Calpain-2 in the brain: Dr. Jekill and Mr Hyde?
Curr. Neuropharmacol.
Altered calcium homeostasis and mitochondrial dysfunction in cortical synaptic compartments of presenilin-1 mutant mice
J. Neurochem.
Neuronal activity regulates the regional vulnerability to amyloid-β deposition
Nat. Neurosci.
Altered Ca2+ dependence of synaptosomal plasma membrane Ca2+-ATPase in human brain affected by Alzheimer’s disease
FASEB J.
Amyloid fibrils induce dysfunction of hippocampal glutamatergic silent synapses
Hippocampus
AβPP-transgenic 2576 mice mimic cell type-specific aspects of Acetyl-CoA-linked metabolic deficits in Alzheimer’s disease
J. Alzheimer’s Dis.
Proteomic screening of glutamatergic mouse brain synaptosomes isolated by fluorescence activated sorting
EMBO J.
A rapid method for the preparation of relatively pure metabolically competent synaptosomes from rat brain
Biochem. J.
Opposite dysregulation of fragile-X mental retardation protein and heteronuclear ribonucleoprotein C protein associates with enhanced APP translation in Alzheimer disease
Mol. Neurobiol.
Cited by (19)
Synaptosomes and Synaptic Vesicles
2022, Encyclopedia of Cell Biology: Volume 1-6, Second EditionAxonal energy metabolism, and the effects in aging and neurodegenerative diseases
2023, Molecular Neurodegeneration